News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
TradingKey Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article reports on an 8K filing by Spruce Power Holding Corp for August 13. It lists the company's stock symbol (SPRU) and its performance on the given date. The content is primarily a brief announcement within a financial news portal, surrounded by various …
Spruce Power Holding Corporation Class A (XLF0) generated €95.20 million in revenue last year, with its Solar Lease Agreements segment being the top performer, contributing €33.98 million. All of the company's revenue came from the United States.
Spruce Power Holding Corporation (SPRU) reported a profit for Q2 2026, with net income attributable to stockholders reaching $3.3 million, up from a $3.0 million loss in the prior year. Despite this improved financial performance, the company disclosed substantial doubt about its ability to …
Citizens has lowered its price target for Spruce Biosciences (NASDAQ: SPRB) from $150.00 to $144.00, citing potential share dilution indicated in the company's 10-Q filing, while maintaining a Market Outperform rating. Despite the reduction, the new target still suggests significant upside, though InvestingPro data …
Citizens Jmp has reduced its price target for Spruce Biosciences (NASDAQ:SPRB) to $144.00 from $150.00 but maintained a "market outperform" rating, indicating a potential upside of nearly 199%. Despite a wider-than-expected quarterly loss of $6.68 per share, analyst sentiment remains largely positive with a …
Citizens has lowered its price target for Spruce Biosciences (NASDAQ:SPRB) from $150.00 to $144.00, citing potential share dilution, while maintaining a Market Outperform rating. Despite the reduction, the new target still indicates significant upside, although InvestingPro data suggests the stock may be overvalued at …
Spruce Biosciences announced its second-quarter 2026 financial results and provided updates on its TA-ERT program for MPS IIIB. The company anticipates submitting a Biologics License Application (BLA) in Q4 2026 and initiating the TrAnsform confirmatory study and an Expanded Access Program (EAP) around the …
Earnings Call Insights: Spruce Power Holding Corporation (SPRU) Q2 2026 MANAGEMENT VIEW * "We delivered a solid second quarter and executed against the priorities we outlined at the beginning of the year." (President, CEO & Chairman Christopher Hayes) * "Disciplined execution across the organization …
Spruce Power reported a solid second quarter in 2026, with operating EBITDA increasing to $26.5 million and net income returning to positive at $3.3 million ($0.14 per share), despite a revenue decline to $30.3 million. The company's profitability improved due to a 21% reduction …
This article announces that Spruce Power Holding Corp has filed a Form 8K for August 12. It briefly mentions the company's stock symbol SPRU and its performance, indicating a +1.44% change. The content primarily serves as a notification of the SEC filing.
Spruce Biosciences (NASDAQ:SPRB) reported a quarterly loss of $6.68 per share, missing the consensus estimate of a $5.79 loss by $0.89. Despite the earnings miss, shares remained flat, and analysts maintain a "Moderate Buy" rating with an average price target of $162.62. The company …
Spruce Biosciences, Inc. (SPRB) reported a significantly widened net loss of $(16.2M) in 2Q 2026, compared to $(2.1M) in 2Q 2025, with diluted loss per share increasing to $(6.68). The company did not report revenue but highlighted regulatory progress with TA-ERT receiving FDA Breakthrough …
Spruce Biosciences (SPRB) reported an increased net loss of $28.5 million for the first half of 2026, up from $16.1 million in 2025, primarily due to higher research and development expenses for its lead asset, tralesinidase alfa (TA-ERT). Despite increased spending, the company significantly …
* Spruce Biosciences press release [https://seekingalpha.com/pr/20616630-spruce-biosciences-reports-second-quarter-2026-financial-results-and-provides-corporate] (SPRB [https://seekingalpha.com/symbol/SPRB]): Q2 GAAP EPS of -$6.68. * Cash and cash equivalents as of June 30, 2026 were $96.3 million, compared to $48.9 million as of December 31, 2025. * Spruce believes that its cash and cash equivalents …
Spruce Biosciences (NASDAQ:SPRB) has secured a $5.5 million strategic investment from the Cure Sanfilippo Foundation and the National MPS Society. This funding will partially support an expanded access program for its investigational therapy, tralesinidase alfa enzyme replacement therapy (TA-ERT), aimed at patients with Sanfilippo …
Spruce Power Holding Corporation Class A (LS:A3EUT8) generated 95.20 million EUR in revenue last year. The majority of this revenue, 33.98 million EUR, came from its Solar Lease Agreements segment. The United States was the primary geographical contributor, accounting for all of the company's …
Spruce Power (NYSE: SPRU) director Jacqueline T. Williams was granted 2,650 restricted stock units (RSUs) on August 4, 2026, as compensation for board service. These RSUs will vest on the first anniversary of the award date. Following this transaction, Williams directly holds a total …
BlackRock, Inc. recently increased its stake in Spruce Biosciences Inc (NASDAQ:SPRB) by 170,898 shares, investing approximately $1,008.96 at $54 per share. This move is notable given Spruce Biosciences' significant decline since its IPO and its current valuation, which GuruFocus identifies as 1032% overvalued based …
Spruce Biosciences, Inc. has appointed Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development. Dr. Cohen Pfeffer brings over a decade of biopharmaceutical industry experience, including her previous role as Executive Medical Director at BioMarin Pharmaceutical. Her appointment is effective immediately, and she was …
Spruce Biosciences (NASDAQ:SPRB) has received a "Moderate Buy" consensus recommendation from eleven brokerages, with an average 12-month price target of $162.63. Despite several firms lowering their price targets recently, new coverage from B. Riley and Craig Hallum maintained buy ratings. The company reported a …
Spruce Power Holding Corporation (NYSE: SPRU) announced it will report its second quarter 2026 financial results after the market closes on Wednesday, August 12. The company will issue a press release and host a conference call and webcast for investors and analysts at 3:30 …
Spruce Biosciences' Chief Medical Officer, Adrian W. Quartel, was granted 13,000 Restricted Stock Units (RSUs) on July 27, 2026. These RSUs, each representing one share of common stock, will vest 25% annually from 2027 through 2030, contingent on his continuous service. This grant aligns …
Spruce Power Holding Corporation Class A (DUS:XLF0) generated 95.20 million EUR in revenue last year, primarily from Solar Lease Agreements, which contributed 33.98 million EUR. The vast majority of this revenue, 95.20 million EUR, originated from the United States. This financial overview highlights the …
Spruce Biosciences (NASDAQ: SPRB) has appointed Adrian Quartel, M.D., FFPM, as its new Chief Medical Officer, effective July 27, 2026. Dr. Quartel brings over 25 years of pharmaceutical experience, having previously served as CMO for several companies and spearheaded the launch of six rare …
Search by ticker symbol or company name and select a result to open its chart.